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About half of the patients treated with docetaxel in the setting of metastatic castration-resis-
tant prostate cancer (CRPC) are non-responders. Therefore, a marker of response would
be beneficial for clinical decision-making. We evaluated class III β-tubulin (βIII-tubulin)
expression as a predictor of resistance in this setting, which previously has been correlated
with lack of response to taxanes in other cancers. Patients with CRPC were included if they
were treated with at least 3 cycles of docetaxel between 1990 and 2011. βIII-tubulin expres-
sion was assessed by immunostaining, which was performed in tissue samples obtained
either via biopsy or prostatectomy at the time of diagnosis. Rates of prostate-specific anti-
gen (PSA) response and overall survival (OS) following docetaxel treatment were compared
between patients with high (2+ or 3+ staining) vs. low (0 or 1+ staining) βIII-tubulin expres-
sion. Of 73 patients, 26 (35%) had a high expression of βIII-tubulin. A PSA decline of 10% or
greater occurred in 65% of patients with a high βIII-tubulin expression vs. 89% with a low
βIII-tubulin expression (p = 0.0267). The median OS for patients with a high βIII-tubulin
expression was 17.4 (95% CI 8.7–21.0) months vs. 19.8 (95% CI 16.6–23.6) months for
patients with a low expression (p = 0.039). Our results show that a high βIII-tubulin expres-
sion is a negative prognostic factor in metastatic CRPC patients treated with docetaxel.
Introduction
Prostate cancer is the most common solid malignancy and the second leading cause of death
by cancer in men [1]. In 2016 alone, 180,890 new cases of prostate cancer were diagnosed in
the United States, which corresponds to 21% of all male malignancies [1]. About 5% of these
patients present with disseminated disease and thus require systemic treatment [1]. Studies
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have shown that between 17–30% of patients with prostate cancer treated with curative intent
will have recurrence and also need systemic therapy [2–4].
The mainstay of the management of patients with metastatic prostate cancer has been
androgen deprivation therapy (ADT) since the 1940s, but most patients still have disease pro-
gression, which is then defined as metastatic CRPC [5–6]. Although recent advances in the
treatment of CRPC include the introduction of new drugs, such as abiraterone and enzaluta-
mide, docetaxel remains one of the main therapeutic choices for most patients [5–6]. About
half of patients receiving docetaxel for CRPC will not respond to therapy, which has propelled
the search for a biomarker to predict response and aid in clinical decision-making [7]. The
need for a marker is especially salient as therapeutic choices for CRPC now include docetaxel,
ADT, and novel androgen-targeting therapy [5–6].
The mechanism of action of docetaxel is to stabilize microtubules, which are filamentous
polymers composed of alpha- and beta-tubulin [7]. Docetaxel binds beta-tubulin, which dis-
rupts the mitotic spindle and arrests cellular reproduction [7]. A mechanism of resistance to
docetaxel is the overexpression of βIII-tubulin in tumor cells, which has been reported to cor-
relate with a lack of treatment response in other types of cancer, such as gastric and lung can-
cer [8–10].
Ploussard and colleagues showed that βIII-tubulin expression was associated with a high
Gleason score and an increased risk of recurrence in a sample of patients with hormone-naïve
prostate cancer [11]. Continuous exposure of prostate cancer cells to docetaxel in vitro
increased βIII-tubulin expression, promoting resistance to the drug. They also found an
increased sensitivity to docetaxel after silencing the βIII-tubulin gene. In the same study,
increased βIII-tubulin expression was associated with a shorter survival in a sample of 37
CRPC patients. To our knowledge, this has been the only study of βIII-tubulin expression in
CRPC patients. We aimed to further evaluate βIII-tubulin as a marker of response to docetaxel
in patients with metastatic CRPC.
Materials and methods
Patients
Adult men with metastatic CRPC treated with at least 3 cycles of docetaxel between 1990 and
2011 were identified retrospectively from the medical records of Henry Ford Hospital (Detroit,
MI, USA). All patients were assessed to have CRPC by their primary oncologists. Only patients
with available prostate cancer specimens were included in our study. Patient demographics,
treatment regimens, prostate-cancer specific information (Gleason score, clinical staging, PSA,
lactic acid dehydrogenase (LDH), alkaline phosphatase, hemoglobin, visceral disease, chemo-
therapy before docetaxel), response rates, and clinical outcomes were abstracted from the med-
ical records. The study was approved by the Henry Ford Health System Institutional Review
Board (IRB) #1 –Henry (IRB00000253) and conducted according to the principles of the Dec-
laration of Helsinki. A waiver of consent was granted by the IRB due to our retrospective study
design.
Tissue specimen and immunostaining
Archival formalin-fixed and paraffin-embedded biopsy specimens were sectioned (4 μm thick)
and attached to glass slides. For tissue microarray construction, four replicate cores with a diam-
eter of 0.6 mm were collected from the donor block of all radical prostatectomy specimens.
Immunostaining was performed with a monoclonal antibody specific for βIII-tubulin isoform
(1:500 dilution, clone TUJ1; Covance, Princeton, NJ, USA). Nerve cells and axons were used as
positive controls and red blood cells as negative. Scoring of immunohistochemical slides was
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classified according to the intensity of cytoplasmic staining in the tumor cells: no detectable
stain = 0, weak stain = 1+, moderate stain = 2+, and strong stain = 3+. A high expression of
βIII-tubulin was defined as at least 1% of the tumor cells having 2+ or 3+ staining, and a low
expression comprised all tumor specimens having 0 or 1+ staining. A weak stain (1+) was con-
sidered negative to reduce the number of false-positives due to background staining. The
pathologist was blinded to the patient’s treatment regimen, response rate and clinical outcome.
Outcome measures
To assess how patients with high or low expression of βIII-tubulin responded to docetaxel
therapy, we compared PSA levels before and after treatment. We used two cutoff points, 10%
and 50%, to categorize the PSA response. We chose a�10% decline in PSA to evaluate any
decline to reduce variation in the measurements due to chance. While a 50% cutoff is more
commonly used in research to detect a more significant difference, a 10% decline in PSA is
more closely related to decision-making in real clinical practice.
We used OS to measure the prognostic impact of βIII-tubulin in patients with high vs low
expression. OS was defined as the period from the date of pathological diagnosis to the date of
death or last follow-up.
Statistical analysis
Comparisons of PSA response between the study groups were made using the Wilcoxon rank-
sum test for continuous variables and the Fisher exact test for categorical variables. Kaplan-
Meier plots and log-rank tests were used to analyze OS. The impact of βIII-tubulin on survival
outcomes was calculated using the Cox proportional hazards model after adjusting for age and
Gleason score. Statistical analyses were performed using SAS 9.4 (SAS Institute Inc, Cary, NC,
USA).
Results
Of 73 patients included in the study, 51% were African-American and 46% were of European
descent, with a mean age of 65.7 ± 7.7 years. Table 1 displays the patient demographics and
clinical characteristics at the time of prostate cancer diagnosis. Biopsy was the most common
source of tissue for immunohistochemistry (77%). The median Gleason score was 8. About
half of patients (52%) did not have metastasis at the time of diagnosis. The average time to met-
astatic CRPC was 5 years, and docetaxel was first-line therapy in 79%.
Table 2 displays the characteristics of patients with a high versus low βIII-tubulin expres-
sion at initiation of docetaxel therapy. The mean number of docetaxel cycles in the high versus
low expression groups was 7.1 and 8.2, respectively. Most patients had an Eastern Cooperative
Oncology Group (ECOG) performance status of<1.
Of the 73 patients, 26 (35%) had a high expression of βIII-tubulin (Fig 1). There was no dif-
ference in the total dose of docetaxel between patients with a high versus low expression of
βIII-tubulin (p = 0.705 by Wilcoxon test). The two groups also did not differ in the following
clinical and pathological characteristics: age, Gleason score, tumor-node-metastasis (TNM)
stage, ECOG performance status, PSA level, LDH level, alkaline phosphatase level, hemoglobin
level, presence of visceral disease, and chemotherapy before docetaxel.
Fig 2 shows the rates of PSA response using the two cutoff points when comparing high ver-
sus low expression of βIII-tubulin. A PSA decline of at least 10% occurend in 65% of patients
with a high expression of βIII-tubulin compared to 89% of patients with a low expression
(p = 0.0267). When using the 50% cutoff, 70% of the patients in the high expression group and
50% in the low expression group had a response of PSA decline, but the difference was not
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statistically significant (p = 0.08; Table 3). The mean PSA levels before and after treatment for
each group are listed in Table 4.
OS for all study patients was 19.2 months (95% CI, 16.0–21.9). The median OS for patients
with a high expression of βIII-tubulin was 17.4 months (95% CI, 8.7–21.0), compared to 19.8
months (95% CI, 16.6–23.6) in patients with a low expression. The log-rank test of equality of
these two OS curves showed that patients with a low expression had a significantly longer sur-
vival time (p = 0.039). Fig 3 illustrates these results in a Kaplan-Meier curve.
The unadjusted hazard ratio (HR) for OS of patients with a high expression of βIII-tubulin,
as compared to those with a low expression, was 1.69 (95% CI, 1.02 to 2.80; p = 0.04). A Cox
proportional hazard model used covariates of Gleason score, age, and expression of βIII-tubu-
lin to assess the influence of these predictors in the HR (Table 5). The adjusted HR for a high
expression of βIII-tubulin was not statistically significant (p = 0.109).
Discussion
This study demonstrates that metastatic CRPC patients with a high expression of βIII-tubulin
had a significantly shorter survival time and worse response rates to docetaxel as indicated by
a 10% or greater decrease in PSA. Our sample included a significant proportion of African-
American patients (51%), which is important because this ethnic group has the highest inci-
dence and mortality of prostate cancer [1]. The baseline characteristics of the study groups had
no significant differences, reflecting a homogeneous sample. The median OS for a high expres-
sion of βIII-tubulin was 17.4 months and for low expression of βIII-tubulin was 19.8 months,
which represents a clinically meaningful difference. The unadjusted HR for a high expression
of βIII-tubulin was statistically significant, but the HR for high expression when adjusted to
Gleason score and age was not. This may indicate that our sample size was not large enough to
detect a less evident difference, given that baseline characteristics were not different between
groups. We also found no statistical difference when comparing groups using a PSA cutoff of
50% (most frequently used in the literature), whereas a PSA decrease of at least 10% (most
Table 1. Patient demographics and clinical characteristics at the time of diagnosis.
Characteristic Number of patients %
Race
African-American 37 51
European descent 34 46
Other 2 3
Mean age, years (min-max) 65.7 (44–84.5)
Source of tissue for Immunohistochemistry
Biopsy 56 77









TNM, tumor, node, metastasis; M0, no distant metastasis; M1, there is distant metastasis.
https://doi.org/10.1371/journal.pone.0222510.t001
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reflective of clinical practice) was significant. This finding might also be attributed to our sam-
ple size.
One limitation of our study is its retrospective nature, which precluded a formal definition
for the CRPC status. Another limitation is that the tissues were obtained from the time of diag-
nosis and not the time of docetaxel therapy. However, some degree of correlation is still
expected between samples, which was reinforced by the high expression group showing a
worse prognosis. Overall, our results show that a high expression of βIII-tubulin indicates a
shorter OS and a reduced treatment response with docetaxel in metastatic CRPC.
Ploussard and colleagues [11] found that βIII-tubulin expression was an independent pre-
dictor of survival in patients with CRPC undergoing docetaxel chemotherapy. However, they
found no difference in response rates to docetaxel, which could be attributed to the high cutoff
used for PSA decline (75%) and the small sample size. The same group of researchers [12] also
suggested that a high expression of βIII-tubulin was associated with progression of prostate
cancer to the castration-resistant stage. These results indicate that, regardless of the response
to docetaxel, the high expression group already represents a more aggressive tumor, less likely
Table 2. Clinical and pathological characteristics at the time of initiation of docetaxel therapy.
Characteristic High βIII-tubulin Low βIII-tubulin p value
Number of patients (%) 26 (35) 47 (65)
Age, years 0.056
Mean 68.3 ± 9.5 72.8 ± 8.0
ECOG, performance status 0.103
0–1 18 (69) 38 (80)
2–4 6 (23) 8 (17)
PSA, ng/dl 428.6 ± 1072.4 399.5 ± 766.4 0.154
LDH, mg/dl 381.5 ± 439.3 273.7 ± 119.8 0.928
Alkaline phosphatase, mg/dl 216.0 ± 197.1 223.1 ± 217.7 0.931
Hemoglobin, g/dl 11.3 ± 1.8 11.3 ± 1.6 0.854
Visceral disease 0.368
Yes 4 (15) 4 (9)
No 22 (85) 43 (91)
Prior metastatic CRPC therapy 0.836
No 21 (81) 37 (79)
Yes 5 (19) 10 (21)
No. of docetaxel doses 7.1 ± 3.2 8.2 ± 3.7 0.210
Dose intensity, mg/m2� 539.3 ± 234.2 569.1 ± 275.4 0.705
TNM staging 0.276
M0 11 (42) 27 (57)
M1 10 (38) 10 (21)
Mx 5 (19) 10 (21)
Gleason score (diagnosis) 0.225
4–6 1 (4) 8 (17)
7 6 (23) 11 (24)
8–10 19 (73) 27 (59)
βIII-tubulin, class III β-tubulin; ECOG, Eastern Cooperative Oncology Group; PSA, Prostate-specific antigen; LDH, lactate dehydrogenase; CRPC, castration-resistant
prostate cancer; TNM, tumor, node, metastasis; M0, no distant metastasis; M1, there is distant metastasis; Mx, distant metastasis cannot be assessed.
�Total dose delivered during therapy.
https://doi.org/10.1371/journal.pone.0222510.t002
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Fig 1. Expression of class III β-tubulin (βIII-tubulin) in available tissue samples (400x magnification). Tissue obtained via biopsy or surgery of the primary tumor
was analyzed for the presence of βIII-tubulin by immunostaining. (A) Tissue with a high expression of βIII-tubulin (staining intensity 2+ or 3+). (B) Tissue with a low
expression of βIII-tubulin (staining intensity 0 or 1+).
https://doi.org/10.1371/journal.pone.0222510.g001
Fig 2. Class III β-tubulin (βIII-tubulin) expression and response to treatment with different PSA cutoffs. βIII-
tubulin expression was considered high if immunostaining was moderate or strong (2+ or 3+) and low if staining was
absent or weak (0 or 1+). Response to treatment was assessed via PSA measurement. Results were statistically
significant when comparing percentage of patients with high vs. low expression of βIII-tubulin using the 10% cutoff
(p = 0.0267).
https://doi.org/10.1371/journal.pone.0222510.g002
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Table 3. Response to docetaxel treatment per βIII-tubulin expression status.
Response High βIII-tubulin Low βIII-tubulin p value
No. % No. %
� 10% PSA decline 17 65 42 89 0.0267
� 50% PSA decline 13 50 33 70 0.0867
βIII-tubulin, class III β-tubulin; No., number of patients; PSA, prostate-specific antigen.
https://doi.org/10.1371/journal.pone.0222510.t003
Table 4. Mean PSA values before and after docetaxel treatment.
Group PSA, ng/dl (mean ± SD) p value
High βIII-tubulin Low βIII-tubulin
Before treatment 428.6 ± 1072.4 399.5 ± 766.4 0.154
After treatment—10% cutoff
Responders 314.7 ± 797.5 192.2 ± 554.4 0.514
Non-responders 224.0 ± 336.2 579.5 ± 592.8 0.092
After treatment—50% cutoff
Responders 80.8 ± 206.1 69.6 ± 215.7 0.714
Non-responders 468.6 ± 876.6 621.6 ± 885.4 0.269
After treatment—all patients 283.2 ± 665.4 234.0 ± 564.8 0.601
PSA, prostate-specific antigen; SD, standard deviation; βIII-tubulin, class III β-tubulin.
https://doi.org/10.1371/journal.pone.0222510.t004
Fig 3. Kaplan-Meier curve of overall survival (OS) according to class III β-tubulin (βIII-tubulin) positivity.
Proportion of patients that were alive over time in years from the date of pathological diagnosis. Patients were
considered to have low expression if the immunostaining was absent (0) or weak (1+) and high expression if staining
was moderate (2+) or strong (3+). Log-rank test of equality showed significantly longer survival time in patient with a
low βIII-tubulin expression (p = 0.039). Median overall survival was 17.4 months in the high expression group and
19.8 months in the low expression group. The unadjusted HR for OS was 1.69 for the group with a high βIII-tubulin
expression (95% CI, 1.02–2.80; p = 0.04).
https://doi.org/10.1371/journal.pone.0222510.g003
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to be controlled with ADT. Thus, besides high expression of βIII-tubulin being a marker of
resistance to docetaxel, it is possible that these patients will have a worse response to any treat-
ment and a worse prognosis overall.
The resistance to docetaxel associated with a high expression of βIII-tubulin has also been
suggested in many other types of human cancers. In breast cancer, docetaxel is still one of the
most used drugs for chemotherapy, and multiple studies have shown the correlation of a
higher expression of βIII-tubulin with worse response to treatment [13–15]. This correlation
was also demonstrated in melanoma [16], head and neck [17], ovarian [18–20], gastric [10, 21]
and non-small-cell lung cancers [9, 22]. Lee and colleagues [23] showed that pancreatic can-
cers have a high expression of βIII-tubulin, which could be related to the high resistance of
these tumors to taxanes and the poor prognosis of this type of cancer.
The mechanism of the induced resistance is not completely understood, but a few studies
have provided theoretical explanations. As mentioned, as docetaxel and other taxanes bind
tubulin and arrest cellular reproduction, the drug then increases the mass of polymerized
tubulin, which is assembled into microtubules and leads to disruption of the mitotic spindle
[7, 24]. Hari and colleagues [25] hypothesized that a high expression of βIII-tubulin results in
decreased tubulin polymerization and microtubule assembly, which opposes the intended
action of taxanes. Galmarini and colleagues [26] suggested two other hypotheses: a) that differ-
ent classes of tubulin would confer different dynamics to the microtubules, altering sensitivity
to taxanes; and b) that taxanes have a preferential binding to certain types of tubulin, and these
would not include the βIII isoform.
The finding of a biomarker to select CRPC patients who might respond better to taxane
therapy would be of great clinical significance. This search for a biomarker became even more
important with the introduction of new first-line therapies for CRPC, such as abiraterone and
enzalutamide, because patients with tumors resistant to taxanes might benefit more from these
drugs. Our study suggests that βIII-tubulin expression might be an important predictor of
response and potentially be a factor in clinical decision-making when selecting patients for tax-
ane chemotherapy in the metastatic CRPC setting. However, one important consideration is
that most of our patients (65%) with a high expression of βIII-tubulin responded to docetaxel
treatment, which means that βIII-tubulin is unlikely to be the sole determinant in identifying
which patients will benefit from docetaxel. Thus, additional markers need to be studied. Pro-
spective studies with larger samples are also needed to better assess the value of βIII-tubulin in
clinical practice.
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